- Former radio personality Radene Marie Cook rues 'fail first' treatment plans for chronic pain
- Ensuring access to chronic pain medications
- Shire extends expiration date for offer to buy ViroPharma
- Obesity drug beloranib shows promise in Prader-Willi population in Phase 2 trials
- Study: Whooping cough vaccine may not prevent infection
EXTON, Pa. — Drug maker ViroPharma has launched an education campaign focused on a rare, debilitating and life-threatening genetic disorder.
The company announced Wednesday the launch of the unbranded campaign focused on hereditary angioedema, particularly the emotional and psychological burden faced by patients with the disease, which results from deficiency of the human plasma protein C1 inhibitor and causes attacks of swelling and pain.
The company said HAE patients can experience multiple attacks per month, but attacks are highly variable and unpredictable, causing patients to experience anxiety, depression and isolation.
"Through this campaign, we hope to illustrate that HAE is not just an acute clinical condition, but can also be an emotional and psychological burden to patients," ViroPharma associate director of marketing Frank Nazzario said. "HAE is a life-altering disease that interferes with work, school, travel and social life."